Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Vascular access for hemodialysis: A perpetual challenge.

Murea M, Geary RL, Davis RP, Moossavi S.

Semin Dial. 2019 Jun 17. doi: 10.1111/sdi.12828. [Epub ahead of print] Review.

PMID:
31209966
2.

APOL1 and Mortality in Patients on Dialysis.

Murea M, Ma L, Freedman BI.

Cardiorenal Med. 2019;9(4):261-264. doi: 10.1159/000501303. Epub 2019 Jun 11. No abstract available.

3.

Nephropathy Progression in African Americans With a Family History of ESKD: Implications for Clinical Trials in APOL1-Associated Nephropathy.

Freedman BI, Spainhour M, Hicks PJ, Turner J, Robertson J, Langefeld CD, Murea M, Divers J.

Am J Kidney Dis. 2019 May 7. pii: S0272-6386(19)30638-9. doi: 10.1053/j.ajkd.2019.03.414. [Epub ahead of print] No abstract available.

PMID:
31076172
4.

A randomized pilot study comparing graft-first to fistula-first strategies in older patients with incident end-stage kidney disease: Clinical rationale and study design.

Murea M, Geary RL, Edwards MS, Moossavi S, Davis RP, Goldman MP, Hurie J, Williams TK, Velazquez-Ramirez G, Robinson TW, Bagwell B, Tuttle AB, Callahan KE, Rocco MV, Houston DK, Pajewski NM, Divers J, Freedman BI, Williamson JD.

Contemp Clin Trials Commun. 2019 Apr 9;14:100357. doi: 10.1016/j.conctc.2019.100357. eCollection 2019 Jun.

5.

Psoas and Paraspinous Muscle Measurements on Computed Tomography Predict Mortality in European Americans with Type 2 Diabetes Mellitus.

Tucker BM, Hsu FC, Register TC, Xu J, Smith SC, Murea M, Bowden DW, Freedman BI, Lenchik L.

J Frailty Aging. 2019;8(2):72-78. doi: 10.14283/jfa.2019.5.

PMID:
30997919
6.

A Single-Center Retrospective Study of Acute Kidney Injury Incidence in Patients With Advanced Malignancies Treated With Antimitochondrial Targeted Drug.

Anderson EM, Zhang J, Russell G, Bowline IG, Thyagarajan B, Li D, Ma L, Anderson ER, Murea M.

Kidney Int Rep. 2018 Oct 29;4(2):310-320. doi: 10.1016/j.ekir.2018.10.021. eCollection 2019 Feb.

7.

Vascular access: HD patients' perceived knowledge and practices.

Cabrera MA, Marshall CN, Sadler KA, Murea M.

Nurs Manage. 2018 Nov;49(11):31-36. doi: 10.1097/01.NUMA.0000547260.22709.0f. No abstract available.

PMID:
30376472
8.

The physiology of uric acid and the impact of end-stage kidney disease and dialysis.

Murea M, Tucker BM.

Semin Dial. 2019 Jan;32(1):47-57. doi: 10.1111/sdi.12735. Epub 2018 Jul 10. Review.

PMID:
29989213
9.

Psoas and paraspinous muscle index as a predictor of mortality in African American men with type 2 diabetes mellitus.

Murea M, Lenchik L, Register TC, Russell GB, Xu J, Smith SC, Bowden DW, Divers J, Freedman BI.

J Diabetes Complications. 2018 Jun;32(6):558-564. doi: 10.1016/j.jdiacomp.2018.03.004. Epub 2018 Mar 19.

10.

JC polyoma viruria associates with protection from chronic kidney disease independently from apolipoprotein L1 genotype in African Americans.

Freedman BI, Kistler AL, Skewes-Cox P, Ganem D, Spainhour M, Turner J, Divers J, Langefeld CD, Murea M, Hicks PJ, Hemal AK, Snipes JA, Zhao L, Abend JR, Lyles DS, Ma L, Skorecki KL.

Nephrol Dial Transplant. 2018 Nov 1;33(11):1960-1967. doi: 10.1093/ndt/gfx368.

PMID:
29420808
11.

Vascular Access Placement Order and Outcomes in Hemodialysis Patients: A Longitudinal Study.

Murea M, Brown WM, Divers J, Moossavi S, Robinson TW, Bagwell B, Burkart JM, Freedman BI.

Am J Nephrol. 2017;46(4):268-275. doi: 10.1159/000481313. Epub 2017 Sep 21.

PMID:
28930719
12.

Efficacy and safety of low-dose heparin in hemodialysis.

Murea M, Russell GB, Daeihagh P, Saran AM, Pandya K, Cabrera M, Burkart JM, Freedman BI.

Hemodial Int. 2018 Jan;22(1):74-81. doi: 10.1111/hdi.12563. Epub 2017 Apr 18.

PMID:
28418614
13.

APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.

Ma L, Chou JW, Snipes JA, Bharadwaj MS, Craddock AL, Cheng D, Weckerle A, Petrovic S, Hicks PJ, Hemal AK, Hawkins GA, Miller LD, Molina AJ, Langefeld CD, Murea M, Parks JS, Freedman BI.

J Am Soc Nephrol. 2017 Apr;28(4):1093-1105. doi: 10.1681/ASN.2016050567. Epub 2016 Nov 7.

14.

Finding the right hemodialysis vascular access in the elderly: a patient-centered approach.

Murea M, Burkart J.

J Vasc Access. 2016 Sep 21;17(5):386-391. doi: 10.5301/jva.5000590. Epub 2016 Aug 1. Review.

PMID:
27516143
15.

Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.

Faig J, Haughton M, Taylor RC, D'Agostino RB Jr, Whelen MJ, Porosnicu Rodriguez KA, Bonomi M, Murea M, Porosnicu M.

Am J Clin Oncol. 2018 May;41(5):432-440. doi: 10.1097/COC.0000000000000301.

16.

Looking Beyond "Fistula First" in the Elderly on Hemodialysis.

Murea M, Satko S.

Semin Dial. 2016 Sep;29(5):396-402. doi: 10.1111/sdi.12481. Epub 2016 Mar 2. Review.

PMID:
26931575
17.

Characterization of circulating APOL1 protein complexes in African Americans.

Weckerle A, Snipes JA, Cheng D, Gebre AK, Reisz JA, Murea M, Shelness GS, Hawkins GA, Furdui CM, Freedman BI, Parks JS, Ma L.

J Lipid Res. 2016 Jan;57(1):120-30. doi: 10.1194/jlr.M063453. Epub 2015 Nov 18.

18.

Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells.

Cheng D, Weckerle A, Yu Y, Ma L, Zhu X, Murea M, Freedman BI, Parks JS, Shelness GS.

J Lipid Res. 2015 Aug;56(8):1583-93. doi: 10.1194/jlr.M059733. Epub 2015 Jun 18.

19.

Structural and functional assessment of the brain in European Americans with mild-to-moderate kidney disease: Diabetes Heart Study-MIND.

Murea M, Hsu FC, Cox AJ, Hugenschmidt CE, Xu J, Adams JN, Raffield LM, Whitlow CT, Maldjian JA, Bowden DW, Freedman BI.

Nephrol Dial Transplant. 2015 Aug;30(8):1322-9. doi: 10.1093/ndt/gfv030. Epub 2015 Feb 26.

20.

Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.

Ma L, Shelness GS, Snipes JA, Murea M, Antinozzi PA, Cheng D, Saleem MA, Satchell SC, Banas B, Mathieson PW, Kretzler M, Hemal AK, Rudel LL, Petrovic S, Weckerle A, Pollak MR, Ross MD, Parks JS, Freedman BI.

J Am Soc Nephrol. 2015 Feb;26(2):339-48. doi: 10.1681/ASN.2013091017. Epub 2014 Jul 10.

21.

Risk of catheter-related bloodstream infection in elderly patients on hemodialysis.

Murea M, James KM, Russell GB, Byrum GV 3rd, Yates JE, Tuttle NS, Bleyer AJ, Burkart JM, Freedman BI.

Clin J Am Soc Nephrol. 2014 Apr;9(4):764-70. doi: 10.2215/CJN.07710713. Epub 2014 Mar 20.

22.

Gene-gene interactions in APOL1-associated nephropathy.

Divers J, Palmer ND, Lu L, Langefeld CD, Rocco MV, Hicks PJ, Murea M, Ma L, Bowden DW, Freedman BI.

Nephrol Dial Transplant. 2014 Mar;29(3):587-94. doi: 10.1093/ndt/gft423. Epub 2013 Oct 24.

23.

Erratum: Enigmatic pruritus in a kidney transplant patient.

Yates JE, Bleyer AJ, Yosipovitch G, Sangueza OP, Murea M.

Clin Kidney J. 2013 Jun;6(3):363. doi: 10.1093/ckj/sft053.

24.

JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy.

Divers J, Núñez M, High KP, Murea M, Rocco MV, Ma L, Bowden DW, Hicks PJ, Spainhour M, Ornelles DA, Kleiboeker SB, Duncan K, Langefeld CD, Turner J, Freedman BI.

Kidney Int. 2013 Dec;84(6):1207-13. doi: 10.1038/ki.2013.173. Epub 2013 May 15.

25.

Enigmatic pruritus in a kidney transplant patient.

Yates JE, Bleyer AJ, Yosipovitch G, Sangueza OP, Murea M.

Clin Kidney J. 2013 Apr;6(2):194-8. doi: 10.1093/ckj/sft009. Erratum in: Clin Kidney J. 2013 Jun;6(3):363.

26.

An ACACB variant implicated in diabetic nephropathy associates with body mass index and gene expression in obese subjects.

Ma L, Murea M, Snipes JA, Marinelarena A, Krüger J, Hicks PJ, Langberg KA, Bostrom MA, Cooke JN, Suzuki D, Babazono T, Uzu T, Tang SC, Mondal AK, Sharma NK, Kobes S, Antinozzi PA, Davis M, Das SK, Rasouli N, Kern PA, Shores NJ, Rudel LL, Blüher M, Stumvoll M, Bowden DW, Maeda S, Parks JS, Kovacs P, Hanson RL, Baier LJ, Elbein SC, Freedman BI.

PLoS One. 2013;8(2):e56193. doi: 10.1371/journal.pone.0056193. Epub 2013 Feb 27.

27.

Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study.

Murea M, Register TC, Divers J, Bowden DW, Carr JJ, Hightower CR, Xu J, Smith SC, Hruska KA, Langefeld CD, Freedman BI.

BMC Nephrol. 2012 Nov 14;13:148. doi: 10.1186/1471-2369-13-148.

28.

Glycated albumin, not hemoglobin A1c, predicts cardiovascular hospitalization and length of stay in diabetic patients on dialysis.

Murea M, Moran T, Russell GB, Shihabi ZK, Byers JR, Andries L, Bleyer AJ, Freedman BI.

Am J Nephrol. 2012;36(5):488-96. doi: 10.1159/000343920. Epub 2012 Nov 7.

PMID:
23147746
29.

Advanced kidney failure and hyperuricemia.

Murea M.

Adv Chronic Kidney Dis. 2012 Nov;19(6):419-24. doi: 10.1053/j.ackd.2012.07.008. Review.

PMID:
23089278
30.

Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications.

Murea M, Ma L, Freedman BI.

Rev Diabet Stud. 2012 Spring;9(1):6-22. doi: 10.1900/RDS.2012.9.6. Epub 2012 May 10. Review.

31.

Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.

Freedman BI, Langefeld CD, Turner J, Núñez M, High KP, Spainhour M, Hicks PJ, Bowden DW, Reeves-Daniel AM, Murea M, Rocco MV, Divers J.

Kidney Int. 2012 Oct;82(7):805-11. doi: 10.1038/ki.2012.217. Epub 2012 Jun 13.

32.

Target organ damage in African American hypertension: role of APOL1.

Freedman BI, Murea M.

Curr Hypertens Rep. 2012 Feb;14(1):21-8. doi: 10.1007/s11906-011-0237-4. Review.

33.

Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.

Freedman BI, Langefeld CD, Murea M, Ma L, Otvos JD, Turner J, Antinozzi PA, Divers J, Hicks PJ, Bowden DW, Rocco MV, Parks JS.

Nephrol Dial Transplant. 2011 Nov;26(11):3805-10. doi: 10.1093/ndt/gfr542. Epub 2011 Sep 19.

34.

Antimicrobial catheter locks: searching for the ideal solution.

Bleyer AJ, Murea M.

J Am Soc Nephrol. 2011 Oct;22(10):1781-2. doi: 10.1681/ASN.2011080839. Epub 2011 Sep 15. No abstract available.

35.

The effect of ACACB cis-variants on gene expression and metabolic traits.

Ma L, Mondal AK, Murea M, Sharma NK, Tönjes A, Langberg KA, Das SK, Franks PW, Kovacs P, Antinozzi PA, Stumvoll M, Parks JS, Elbein SC, Freedman BI.

PLoS One. 2011;6(8):e23860. doi: 10.1371/journal.pone.0023860. Epub 2011 Aug 26.

36.

Genome-wide association scan for survival on dialysis in African-Americans with type 2 diabetes.

Murea M, Lu L, Ma L, Hicks PJ, Divers J, McDonough CW, Langefeld CD, Bowden DW, Freedman BI.

Am J Nephrol. 2011;33(6):502-9. doi: 10.1159/000327985. Epub 2011 May 5.

37.

The APOL1 gene and allograft survival after kidney transplantation.

Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI.

Am J Transplant. 2011 May;11(5):1025-30. doi: 10.1111/j.1600-6143.2011.03513.x. Epub 2011 Apr 12.

38.

Protein kinase C-β gene variants and type 2 diabetes-associated kidney failure: What can we learn from gene association studies in diabetic nephropathy?

Freedman BI, Bowden DW, Murea M.

Am J Kidney Dis. 2011 Feb;57(2):194-7. doi: 10.1053/j.ajkd.2010.10.042. Epub 2010 Dec 13. No abstract available.

39.

Lipotoxicity in diabetic nephropathy: the potential role of fatty acid oxidation.

Murea M, Freedman BI, Parks JS, Antinozzi PA, Elbein SC, Ma L.

Clin J Am Soc Nephrol. 2010 Dec;5(12):2373-9. doi: 10.2215/CJN.08160910. Epub 2010 Nov 4. Review.

40.

Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function.

Murea M, Park JK, Sharma S, Kato H, Gruenwald A, Niranjan T, Si H, Thomas DB, Pullman JM, Melamed ML, Susztak K.

Kidney Int. 2010 Sep;78(5):514-22. doi: 10.1038/ki.2010.172. Epub 2010 Jun 9.

41.

The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans.

Freedman BI, Edberg JC, Comeau ME, Murea M, Bowden DW, Divers J, Alarcón GS, Brown EE, McGwin G Jr, Kopp JB, Winkler CA, Nelson GW, Illei G, Petri M, Ramsey-Goldman R, Reveille JD, Vilá LM, Langefeld CD, Kimberly RP; PROFILE Study Group.

Am J Nephrol. 2010;32(1):66-72. doi: 10.1159/000314688. Epub 2010 Jun 7.

42.

Potential effects of MYH9-associated nephropathy on dialysis and kidney transplant outcomes.

Freedman BI, Murea M.

Semin Dial. 2010 May-Jun;23(3):244-7. doi: 10.1111/j.1525-139X.2010.00721.x. Epub 2010 May 10. Review.

43.

Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).

Deshpande P, Chen J, Gofran A, Murea M, Golestaneh L.

Nephrol Dial Transplant. 2010 Aug;25(8):2632-6. doi: 10.1093/ndt/gfq090. Epub 2010 Feb 24.

PMID:
20181801
44.

Essential hypertension and risk of nephropathy: a reappraisal.

Murea M, Freedman BI.

Curr Opin Nephrol Hypertens. 2010 May;19(3):235-41. doi: 10.1097/MNH.0b013e3283366344. Review.

45.

The pathogenic role of Notch activation in podocytes.

Niranjan T, Murea M, Susztak K.

Nephron Exp Nephrol. 2009;111(4):e73-9. doi: 10.1159/000209207. Epub 2009 Mar 17. Review.

Supplemental Content

Support Center